0 CHECKOUT

Moderate Pain - Pipeline Review, H2 2015

  • ID: 3455165
  • September 2015
  • 93 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amorsa Therapeutics Inc.
  • Egalet Corporation
  • KemPharm, Inc.
  • Nektar Therapeutics
  • Pain Therapeutics, Inc.
  • Pfizer Inc.
  • MORE

Moderate Pain - Pipeline Review, H2 2015

Summary

The report ‘Moderate Pain - Pipeline Review, H2 2015’, provides an overview of the Moderate Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amorsa Therapeutics Inc.
  • Egalet Corporation
  • KemPharm, Inc.
  • Nektar Therapeutics
  • Pain Therapeutics, Inc.
  • Pfizer Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Moderate Pain Overview

Therapeutics Development

Pipeline Products for Moderate Pain - Overview

Pipeline Products for Moderate Pain - Comparative Analysis

Moderate Pain - Therapeutics under Development by Companies

Moderate Pain - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Moderate Pain - Products under Development by Companies

Moderate Pain - Companies Involved in Therapeutics Development

A. Menarini Industrie Farmaceutiche Riunite Srl

Amorsa Therapeutics Inc.

Charleston Laboratories, Inc.

Egalet Corporation

Elite Pharmaceuticals, Inc.

KemPharm, Inc.

Laboratorios Del Dr. Esteve S.A.

Lumosa Therapeutics Co., Ltd.

Nektar Therapeutics

Pacira Pharmaceuticals, Inc.

Pain Therapeutics, Inc.

Pfizer Inc.

Purdue Pharma L.P.

Relmada Therapeutics, Inc.

Teva Pharmaceutical Industries Limited

Trevena, Inc.

Moderate Pain - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(benzhydrocodone hydrochloride + acetaminophen) IR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(celecoxib + tramadol hydrochloride) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(dexketoprofen + tramadol hydrochloride) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(hydrocodone bitartrate + acetaminophen) IR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

buprenorphine hydrochloride ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CL-108 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CLH-10 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CLH-5 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Egalet-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ketamine hydrochloride ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

levorphanol tartrate ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LT-1001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

meloxicam ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

morphine sulfate ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NKTR-181 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OLT-1177 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

oxycodone hydrochloride ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

oxycodone hydrochloride ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TRV-734 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

V-116517 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Moderate Pain - Recent Pipeline Updates

Moderate Pain - Dormant Projects

Moderate Pain - Discontinued Products

Moderate Pain - Product Development Milestones

Featured News & Press Releases

Mar 04, 2014: KemPharm Expands Global Intellectual Property Estate for KP201

Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-001

Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-002 for Moderate to Severe Pain

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Moderate Pain, H2 2015

Number of Products under Development for Moderate Pain - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Moderate Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015

Moderate Pain - Pipeline by Amorsa Therapeutics Inc., H2 2015

Moderate Pain - Pipeline by Charleston Laboratories, Inc., H2 2015

Moderate Pain - Pipeline by Egalet Corporation, H2 2015

Moderate Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2015

Moderate Pain - Pipeline by KemPharm, Inc., H2 2015

Moderate Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015

Moderate Pain - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015

Moderate Pain - Pipeline by Nektar Therapeutics, H2 2015

Moderate Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2015

Moderate Pain - Pipeline by Pain Therapeutics, Inc., H2 2015

Moderate Pain - Pipeline by Pfizer Inc., H2 2015

Moderate Pain - Pipeline by Purdue Pharma L.P., H2 2015

Moderate Pain - Pipeline by Relmada Therapeutics, Inc., H2 2015

Moderate Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015

Moderate Pain - Pipeline by Trevena, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Moderate Pain Therapeutics - Recent Pipeline Updates, H2 2015

Moderate Pain - Dormant Projects, H2 2015

Moderate Pain - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Moderate Pain, H2 2015

Number of Products under Development for Moderate Pain - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

A. Menarini Industrie Farmaceutiche Riunite Srl
Amorsa Therapeutics Inc.
Charleston Laboratories, Inc.
Egalet Corporation
Elite Pharmaceuticals, Inc.
KemPharm, Inc.
Laboratorios Del Dr. Esteve S.A.
Lumosa Therapeutics Co., Ltd.
Nektar Therapeutics
Pacira Pharmaceuticals, Inc.
Pain Therapeutics, Inc.
Pfizer Inc.
Purdue Pharma L.P.
Relmada Therapeutics, Inc.
Teva Pharmaceutical Industries Limited
Trevena, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Baxter International Inc.
  • Endo International Plc.
  • Medtronic, Inc.
  • Johnson & Johnson Services, Inc.
  • Procter & Gamble Co.
  • Purdue Pharma L.P.